Hypertrophic Cardiomyopathy Treatment: Present and Future Paths

Table of Contents

Hypertrophic cardiomyopathy (HCM) is a condition characterized by abnormal thickening of the heart muscle, impeding effective blood pumping. It can affect individuals of all ages, leading to long-term health implications. Key symptoms of HCM include shortness of breath, chest pain, fainting, palpitations, and occasional headaches

Introduction to Hypertrophic Cardiomyopathy:

Hypertrophic cardiomyopathy (HCM) is a complex and relatively common heart condition characterized by the abnormal thickening of the heart muscle. This condition can impede the heart’s ability to pump blood efficiently, leading to a range of symptoms and potential complications. HCM is a heterogeneous disorder that affects individuals of all ages and can have a significant impact on their quality of life.

This introduction will provide an overview of HCM, including its causes, symptoms, diagnosis, and available treatments.

Market Size for Hypertrophic Cardiac Myopathy Treatment

The hypertrophic heart disease treatment market can be segmented by type of disease, diagnosis, treatment and distribution channel.

These segments’ growth will allow you to identify the meager growth segments within the industry and give users a market overview.

Disease Type

Treatment for obstructive hypertrophic cardiomyopathy
Treatment of non-obstructive hypertrophic cardiomyopathy

Diagnosis

Chest X-Ray
Echocardiogram
Electrocardiogram (ECG).
Treadmill Stress Test
Blood Tests
Genetic Testing Or Screening

Treatment

Medication
Surgically implanted devices
Nonsurgical Procedures

End-User

Hospitals
Research Institutes
Specialty Clinics

Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacies
Other

Drivers:

Treatment of hypertrophic cardiomyopathy

According to the American Heart Association, in March 2016, hypertrophic heart disease treatment affected approximately 500,000 Americans annually. According to European Heart Journal findings from July 2014, HCM affects 1 in 500 people worldwide. This translates into about 700,000 Americans.

Opportunities

Obesity Increase

In HCM, being overweight is associated with a higher rate of heart failure (HF). The burden of obesity, overweight and the associated risk of heart failure in hypertrophic cardiomyopathy (HCM), patients who are obese, demands that therapeutics be available for treatment. This is driving market growth.

An increase in the number research and development activities

An increase in R&D activity is driving the market growth. In May 2018, MyoKardia, Inc. began the PIONEER Open-label Extension (OLE) Study of its investigational mavacamten drug, which will be used for symptomatic, obstructive, hypertrophic cardiomyopathy treatments. In a May 2018 study published in Journal of General Physiology, researchers from Washington State University found a link between genetic mutations and the mode of disruption of heart function.

Prominent players in the hypertrophic cardiomyopathy treatment market comprise:

Alexion Pharmaceuticals, Inc. (U.S.)
Sanofi (France)
Takeda Pharmaceutical Company Limited (Japan)
Vertex Pharmaceuticals Incorporated (U.S.)
F. Hoffmann-La Roche Ltd (Switzerland)
Abbott (U.S.)
Amgen Inc. (U.S.)
Jazz Pharmaceuticals, Inc. (U.K.)
Pfizer Inc. (U.S.)
PerkinElmer Inc. (U.S.)
Bio-Rad Laboratories, Inc. (U.S.)
Novartis AG (Switzerland)
Sun Pharmaceutical Industries Ltd. (India)

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.

Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.